Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7670296

[Screening coloscopy: when and how?].

H Neuhaus
View original source ↗Export metadata ↓

Abstract

Screening colonoscopy aims at a reduction of colorectal cancer mortality. The efficacy is undetermined due to lack of controlled trials. However, screening colonoscopy is generally accepted in asymptomatic patient with a considerably increased risk for carcinoma in particular in case of familial adenomatous polyposis coli, hereditary nonpolypous colorectal cancer syndrome and adenomas detected by sigmoidoscopy. A positive cost/benefit ratio can also be expected in first-degree relatives of patients with familial sporadic colorectal carcinoma. To date the efficacy of colonoscopic surveillance of patients with extensive ulcerative colitis remains undetermined in spite of an increased risk of cancer in the long-term course. In people with an average risk for colorectal cancer the probability of a development of carcinoma might be reduced by about 45% by once-only sigmoidoscopy performed at the age of 50-60 years. Further reduction can theoretically be expected from routine colonoscopy. However, before a general recommendation can be given, the efficacy must be proved in a randomised controlled trial.

Explore related subjects

Adenomatous Polyposis ColiAdultAgedColonic NeoplasmsColonic PolypsColonoscopyColorectal Neoplasms, Hereditary NonpolyposisCost-Benefit AnalysisFemaleHumansMaleMass ScreeningMiddle AgedEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Neuhaus. 1995. [Screening coloscopy: when and how?].. https://pubmed.ncbi.nlm.nih.gov/7670296/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Familial adenomatous polyposis patients have high levels of arachidonic acid and docosahexaenoic acid and low levels of linoleic acid and alpha-linolenic acid in serum phospholipids.

Familial adenomatous polyposis (FAP) provides a model of APC inactivation as an early genetic event for the approximately 85% of colorectal cancers that develop from polyps. Abnormal fatty acid composition of tissues and serum phospholipids has been linked to cancer risk. Our aim was to describe the composition of fatty acids in serum phospholipids in 38 colectomized FAP patients as compared to 160 healthy subjects. Mean fatty acid intakes were similar between the groups. Colectomy was done on average 16 years prior to inclusion, and 18% were diagnosed with colorectal cancer at colectomy. The levels (weight %) of linoleic and alpha-linolenic acid were higher among the reference subjects (difference: 3.96, 95% confidence interval (CI) = 2.87, 5.04, and difference: 0.06, 95% CI = 0.04, 0.08, respectively), and the levels of arachidonic and docosahexaenoic acid were lower (difference: -3.70, 95% CI = -4.35, -3.06, and difference: -5.26, 95% CI = -6.25, -4.28, respectively) as compared to the FAP patients (all p < or = 0.0001). The abnormal fatty acid composition was not related to time since colectomy, intestinal reconstruction or history of colorectal cancer for any of the fatty acids assessed. Compositional differences in the fatty acid profile of serum phospholipids have not been described before in FAP patients. Further studies are needed to confirm these findings and assess clinical significances of a possible distorted fatty acid metabolism, including a potentially different dietary need of essential fatty acids. The relevance of these findings for APC induced cancers remains unclear.

Adenomatous Polyposis Coli↗
PubMed2007

Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis.

BACKGROUND AND OBJECTIVES: The number of rectal polyps and the site of mutations in the APC (Adenomatous polyposis coli) gene have been used to guide the surgical management in patients with familial adenomatous polyposis (FAP). The aim of this study is to assess the utility of the APC mutation screening compared to the degree of the rectal polyposis in surgical decision making. METHODS: The post-surgical courses of 25 patients submitted to subtotal colectomy with ileorectal anastomosis (IRA) were reviewed. Preservation of the rectum was prospectively decided on the basis of well-defined endoscopic criteria. The number of rectal polyps was assessed preoperatively and every 6-12 months. APC gene was screened for mutations by heteroduplex analysis, single strand conformation polymorphism, in vitro synthesized protein (IVSP), and DNA sequencing. Patients negative for APC mutations were tested for MYH mutations. RESULTS: On the basis of preoperative polyp rectal count we categorized patients as follows: Group I, 5 or fewer adenomas; Group II, 6-9 adenomas; Group III, 10 or more adenomas. After a follow-up ranging from 12 to 225 months we have observed a significant difference of recurrent rectal adenomas between Groups I-II versus III. No difference was detected among patients of Group I and II. The mean number of adenomas/year/patient was 0.67, 1.62, and 9.29 for Group I, II, and III, respectively. Carpeting polyposis of the rectal stump developed in three patients with APC mutation at codon 1309 and two of them needed later proctectomy. Diffuse rectal polyposis was observed in one patient with mutation at exon 9 who had 10 small polyps at time of surgery. Mutation at the 5'-end of APC (codons 144-232), mutation of MYH and unknown APC or MYH mutation were correlated with a low number of polyps both at presentation and follow-up. No IRA patients developed rectal cancer. CONCLUSIONS: In our experience fewer than 10 rectal polyps at presentation can predict a favorable outcome after IRA. Identification of specific germ-line APC or MYH mutation can address the choice of surgical treatment.

Adenomatous Polyposis Coli↗